BAY 390

Product Description

BAY 390 is a potent and selective transient receptor potential ankyrin 1 (TRPA1) antagonist (IC₅₀ values are 16, 63 and 82 nM for hTRPA1 FLIPR, rTRPA1 FLIPR and hTRPA1 Ephys, respectively). In vivo, BAY 390 exhibits efficacy in rat models of inflammatory and neuropathic pain. BAY 390 is orally bioavailable and brain penetrant. Suitable to use as an in vitro or in vivo probe to investigate the roles of TRPA1 in models of acute, inflammatory, and neuropathic pain.

Licensing Information

This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the BAY 390 probe summary on the SGC website.

Solubility

Preparing Stock Solutions for BAY 390

The following data is based on the product molecular weight 277.26

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.61 mL	18.03 mL	36.07 mL
5 mM	0.72 mL	3.61 mL	7.21 mL
10 mM	0.36 mL	1.80 mL	3.61 mL
50 mM	0.07 mL	0.36 mL	0.72 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Mesch Discovery of BAY-390, a selective CNS penetrant chemical probe as transient receptor potential ankyrin 1 (TRPA1) antagonist. J.Med.Chem. 2023 PMID: 36622903